UK markets closed

Saniona AB (publ) (SANION.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
18.12-1.16 (-6.02%)
At close: 5:29PM CEST
Full screen
Previous close19.28
Open19.30
Bid18.14 x 0
Ask18.20 x 0
Day's range18.04 - 19.64
52-week range15.40 - 44.50
Volume307,252
Avg. volume178,369
Market cap1.13B
Beta (5Y monthly)0.66
PE ratio (TTM)N/A
EPS (TTM)-4.06
Earnings date26 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est77.50
  • Globe Newswire

    Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity

    PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Sanio

  • Globe Newswire

    Saniona secures SEK 87 million ($10 million) non-dilutive term loan

    PRESS RELEASE July 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ($10 million) with Formue Nord Fokus A/S. Proceeds from the loan will be used to support Saniona’s clinical development programs and for general working capital purposes. Rami Levin, President & Chief Executive Officer of Saniona, commented, “We just initiated a Phase 1 trial of SAN71

  • Globe Newswire

    Saniona Initiates Phase 1 Clinical Trial of SAN711

    PRESS RELEASE June 30, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of SAN711, a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine. SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 receptors and may be applicable in the treatment of rare neuropathic disorders. Data from the trial are expected in the first half o